ArticleJournal of hematology & oncology2026

Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.

Pritika Sharma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.